FDA Reveals Rejection Letter For MDMA Therapy Application with Dr. Matt Johnson

In this episode of the Illusion of Consensus podcast, Dr. Matt Johnson and I discuss the recent FDA decision regarding MDMA therapy for PTSD. The conversation covers the FDA's commitment to transparency in drug approval processes, the specific concerns raised in the rejection of MDMA therapy, and the implications for future psychedelic treatments. Dr. Johnson emphasizes the need for a fair evaluation process and the potential benefits of MDMA therapy compared to traditional SSRIs, while also addressing the importance of understanding the durability of treatment effects and the biases present in clinical trials.

Chapters

00:00Introduction to Psychedelic Research and FDA Transparency

02:39FDA's Rejection of MDMA Therapy: Key Concerns

04:55Exploring the FDA's Feedback on MDMA Therapy

12:18Durability of MDMA's Effects in PTSD Treatment

16:59Comparing MDMA Therapy to SSRIs for PTSD

20:51Effect Sizes and Future of Psychedelic Treatments

28:38MDMA Use and Treatment Efficacy

32:02Pre-Screening and Selection Bias in Trials

34:38Durability of Treatment Effects

36:32Long-Term Efficacy and Safety of SSRIs

39:29Societal Factors in Mental Health Treatment

42:43The Role of Psychedelics in Therapy

46:50Future of Psychedelic Therapy and FDA Regulations

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.illusionconsensus.com/subscribe